4.584CHF+7.25%Mkt Cap: 1.17B CHFP/E: —Last update: 2026-05-13
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-34.40
PEG—
P/B-0.98
P/S5.14
EV/EBITDA-23.16
EV/Revenue10.40
EPS (TTM)-1.03
EPS (Forward)-0.13
Cash Flow & Leverage
FCF Yield-11.25%
FCF Margin-59.62%
Operating CF-153.23M CHF
CapEx (TTM)13.82M CHF
Net Debt/EBITDA-11.90
Net Debt1.18B CHF
Technical
SMA 503.605 (+27.1%)
SMA 2003.597 (+27.4%)
Beta1.66
S&P 52W Chg24.23%
Avg Vol (30d)1.71M
Avg Vol (10d)2.03M
Technical Indicators
RSI (14)73.6
MACD0.1708
MACD Signal0.1020
MACD Hist.+0.0688
BB Upper4.301 CHF
BB Middle3.831 CHF
BB Lower3.361 CHF
BB Width24.52%
ATR (14)0.2781 CHF
Vol Ratio (20d)2.30x
52W Range
1.25093% of range4.850
52W High4.850 CHF
52W Low1.250 CHF
Profitability
Gross Margin90.52%
EBITDA Margin-44.90%
Profit Margin-50.64%
Oper. Margin-108.00%
ROE9.82%
ROA-23.98%
Revenue Growth-19.90%
Earnings Growth—
Balance Sheet
Debt/Equity-1.11
Current Ratio1.39
Quick Ratio0.81
Book Value/Sh-4.5350 CHF
Cash/Share0.3530 CHF
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CHF
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateJun 16, 2017
Pay DateOct 13, 2020
Ownership
Shares Out.255.04M
Float155.85M
Insiders30.52%
Institutions27.11%
Analyst Consensus
Rating—
Target (Mean)4.500 CHF
Target Range4.000 CHF – 5.000 CHF
# Analysts3
Company
Market Cap1.17B CHF
Enterprise Value2.29B CHF
Revenue (TTM)220.58M CHF
Gross Profit199.67M CHF
Net Income (TTM)-111.70M CHF
Revenue/Share1.027 CHF
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees424
Last Price4.584 CHF
CountryCH
SectorHealthcare
IndustryBiotechnology
ISINCH0363463438